Synonyms: Aidixi® | RC-48 | RC48-ADC
disitamab vedotin is an approved drug
Compound class:
Antibody
Comment: Disitamab vedotin (RC48) is an anti-epidermal growth factor receptor 2 (ERBB2; HER2) antibody-drug conjugate (ADC) [4]. Its cytotoxic payload is the potent antimitotic agent monomethyl auristatin E (MMAE). Antibody binding blocks ERBB2 signalling and intracellular release of MMAE inhibits microtubule formation and induces apoptosis. The antibody may also mediate antibody-dependent cell-mediated cytotoxicity (ADCC).
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. China (2021) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10933 | disitamab vedotin |
Synonyms ![]() |
Aidixi® | RC-48 | RC48-ADC |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 896 |
Other databases | |
GtoPdb PubChem SID | 507750350 |
Search PubMed clinical trials | disitamab vedotin |
Search PubMed titles | disitamab vedotin |
Search PubMed titles/abstracts | disitamab vedotin |